p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity

Cancer Research

Volumn 63, Issue 10, 2003, Pages 2373-2378

  Shiseki, Masayuki ^a   Nagashima, Makoto ^a   Pedeux, Remy M ^a   Kitahama Shiseki, Mariko ^a   Miura, Koh ^a   Okamura, Shu ^a   Onogi, Hitoshi ^a   Higashimoto, Yuichiro ^a   Appella, Ettore ^a   Yokota, Jun ^b   Harris, Curtis C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P300; PROTEIN P53;

ACETYLATION; AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CHROMATIN STRUCTURE; COLORECTAL CANCER; CONTROLLED STUDY; GENE ISOLATION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; P28ING5 GENE; P29ING4 GENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA INTERACTION; PROTEIN PROCESSING; TUMOR SUPPRESSOR GENE;

ACETYLATION; ACETYLTRANSFERASES; AMINO ACID SEQUENCE; CELL CYCLE PROTEINS; CELL DIVISION; CLONING, MOLECULAR; COLORECTAL NEOPLASMS; DNA, COMPLEMENTARY; GROWTH INHIBITORS; HISTONE ACETYLTRANSFERASES; HOMEODOMAIN PROTEINS; HUMANS; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; SEQUENCE HOMOLOGY, AMINO ACID; TRANSCRIPTION FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 0038520190     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Garkavtsev, I., Kazarov, A., Gudkov, A., and Riabowol, K. Suppression of the novel growth inhibitor p33ING1 promotes neoplastic transformation. Nat. Genet., 14: 415-420, 1996.
2. Feng, X., Hara, Y., and Riabowol, K. Different HATS of the ING1 gene family. Trends Cell Biol., 12: 532-538, 2002.
3. Garkavtsev, I., and Riabowol, K. Extension of the replicative life span of human diploid fibroblasts by inhibition of the p33ING1 candidate tumor suppressor. Mol. Cell Biol., 17: 2014-2019, 1997.
4. Helbing, C. C., Veillette, C., Riabowol, K., Johnston, R. N., and Garkavtsev, I. A novel candidate tumor suppressor. ING1, is involved in the regulation of apoptosis. Cancer Res., 57: 1255-1258, 1997.
5. Garkavtsev, I., Grigorian, I. A., Ossovskaya, V. S., Chernov, M. V., Chumakov, P. M., and Gudkov, A. V. The candidate tumour suppressor p33ING1 cooperates with p53 in cell growth control. Nature (Lond.), 391: 295-298, 1998.
6. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. p53 mutations in human cancers. Science (Wash. DC), 253: 49-53, 1991.
7. Greenblatt, M. S., Bennett, W. P., Hollstein, M., and Harris, C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54: 4855-4878, 1994.
8. Hollstein, M., Hergenhahn, M., Yang, Q., Bartsch, H., Wang, Z. Q., and Hainaut, P. New approaches to understanding p53 gene tumor mutation spectra. Mutat. Res., 431: 199-209, 1999.
9. Vogelstein, B., Lane, D., and Levine, A. J. Surfing the p53 network. Nature (Lond.), 408: 307-310, 2000.
10. Garkavtsev, I., Kazarov, A., Gudkov, A., and Riabowol, K. Suppression of the novel growth inhibitor p33ING1 promotes neoplastic transformation. Nat. Genet., 23: 373, 1999.
11. Saito, A., Furukawa, T., Fukushige, S., Koyama, S., Hoshi, M., Hayashi, Y., and Horii, A. p24/ING1-ALT1 and p47/ING1-ALT2, distinct alternative transcripts of p33/ING1. J. Hum. Genet., 45: 177-181, 2000.
12. Aasland, R., Gibson, T. J., and Stewart, A. F. The PHD finger: implications for chromatin-mediated transcriptional regulation. Trends Biochem Sci., 20: 56-59, 1995.
13. Loewith, R., Meijer, M., Lees-Miller, S. P., Riabowol, K., and Young, D. Three yeast proteins related to the human candidate tumor suppressor p33(ING1) are associated with historic acetyltransferase activities. Mol. Cell Biol., 20: 3807-3816, 2000.
14. Kuzmichev, A., Zhang, Y., Erdjument-Bromage, H., Tempst, P., and Reinberg, D. Role of the Sin3-histone deacetylase complex in growth regulation by the candidate tumor suppressor p33(ING1). Mol. Cell Biol., 22: 835-848, 2002.
15. Howe, L., Kusch, T., Muster, N., Chaterji, R., Yates, J. R., III, and Workman, J. L. Yng1p modulates the activity of Sas3p as a component of the yeast NuA3 Hhistone acetyltransferase complex. Mol. Cell Biol., 22: 5047-5053, 2002.
16. Choy, J. S., Tobe, B. T., Huh, J. H., and Kron, S. J. Yng2p-dependent NuA4 histone H4 acetylation activity is required for mitotic and meiotic progression. J. Biol. Chem., 276: 43653-43662, 2001.
17. Skowyra, D., Zeremski, M., Neznanov, N., Li, M., Choi, Y., Uesugi, M., Hauser, C. A., Gu, W., Gudkov, A. V., and Qin, J. Differential association of products of alternative transcripts of the candidate tumor suppressor ING1 with the mSin3/ HDAC1 transcriptional corepressor complex. J. Biol. Chem., 276: 8734-8739, 2000.
18. Vieyra, D., Loewith, R., Scott, M., Bonnefin, P., Boisvert, F. M., Cheema, P., Pastyryeva, S., Meijer, M., Johnston, R. N., Bazett-Jones, D. P., McMahon, S., Cole, M. D., Young, D., and Riabowol, K. Human ING1 proteins differentially regulate historic acetylation. J. Biol. Chem., 277: 29832-29839, 2002.
19. Nagashima, M., Shiseki, M., Miura, K., Hagiwara, K., Linke, S. P., Pedeux, R., Wang, X. W., Yokota, J., Riabowol, K., and Harris, C. C. DNA damage-inducible gene p33ING2 negatively regulates cell proliferation through acetylation of p53. Proc. Natl. Acad. Sci. USA, 98: 9671-9676, 2001.
20. Nagashima, M., Shiseki, M., Pedeux, R. M., Okamura, S., Kitahama-Shiseki, M., Miura, K., Yokota, J., and Harris, C. C. A novel PHD-finger motif protein, p47ING3, modulates p53-mediated transcription, cell cycle control, and apoptosis. Oncogene, 22: 343-350, 2003.
21. Gunduz, M., Ouchida, M., Fukushima, K., Ito, S., Jitsumori, Y., Nakashima, T., Nagai, N., Nishizaki, K., and Shimizu, K. Allelic loss and reduced expression of the ING3, a candidate tumor suppressor gene at 7q31, in human head and neck cancers. Oncogene, 21: 4462-4470, 2002.
22. Kessis, T. D., Slebos, R. J., Nelson, W. G., Kastan, M. B., Plunkett, B. S., Han, S. M., Lorincz, A. T., Hedrick, L., and Cho, K. R. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DA damage. Proc. Natl. Acad. Sci. USA, 90: 3988-3992, 1993.
23. Kusumoto, M., Ogawa, T., Mizumoto, K., Ueno, H., Niiyama, H., Sato, N., Nakamura, M., and Tanaka, M. Adenovirus-mediated p53 gene transduction inhibits telomerase activity independent of its effects on cell cycle arrest and apoptosis in human pancreatic cancer cells. Clin. Cancer Res., 5: 2140-2147, 1999.
24. Baker, S. J., Markowitz, S., Fearon, E. R., Willson, J. K., and Vogelstein, B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science (Wash. DC), 249: 912-915, 1990.
25. Yaciuk, P., and Moran, E. Analysis with specific polyclonal antiserum indicates that the EIA-associated 300-kDa product is a stable nuclear phosphoprotein that undergoes cell cycle phase-specific modification. Mol. Cell Biol., 11: 5389-5397, 1991.
26. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
27. May, P., and May, E. Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene. 18: 7621-7636, 1999.
28. Gu, W., and Roeder, R. G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell, 90: 595-606, 1997.
29. Sakaguchi, K., Herrera, J. E., Saito, S., Miki, T., Bustin, M., Vassilev, A., Anderson, C. W., and Appella, E. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev., 12: 2831-2841, 1998.
30. Liu, L., Scolnick, D. M., Trievel, R. C., Zhang, H. B., Marmorstein, R., Halazonetis, T. D., and Berger, S. L. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol. Cell Biol., 19: 1202-1209, 1999.
31. Luo, J., Nikolaev, A. Y., Imai, S., Chen, D., Su, F., Shiloh, A., Guarente, L., and Gu, W. Negative control of p53 by Sir2α promotes cell survival under stress. Cell, 107: 137-148, 2001.
32. Vaziri, H., Dessain, S. K., Ng, E. E., Imai, S. I., Frye, R. A., Pandita, T. K., Guarente, L., and Weinberg, R. A. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell, 107: 149-159, 2001.
33. Nourani, A., Doyon, Y., Utley, R. T., Allard, S., Lane, W. S., and Cote, J. Role of an ING1 growth regulator in transcriptional activation and targeted historic acetylation by the NuA4 complex. Mol. Cell Biol., 21: 7629-7640, 2001.
34. Prives, C., and Manley, J. L. Why is p53 acetylated? Cell, 107: 815-818, 2001.
35. Barley, N. A., Liu, L., Chehab, N. H., Mansfield, K., Harris, K. G., Halazonetis, T. D., and Berger, S. L. Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol. Cell, 8: 1243-1254, 2001.
36. Espinosa, J. M., and Emerson, B. M. Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Mol. Cell, 8: 57-69, 2001.
37. Kaeser, M. D., and Iggo, R. D. Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo. Proc. Natl. Acad. Sci. USA, 99: 95-100, 2002.
38. Kobet, E., Zeng, X., Zhu, Y., Keller, D., and Lu, H. MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins. Proc. Natl. Acad. Sci. USA, 97: 12547-12552, 2000.
39. Ito, A., Lai, C. H., Zhao, X., Saito, S., Hamilton, M. H., Appella, E., and Yao, T. P. p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J., 20: 1331-1340, 2001.
40. Ito, A., Kawaguchi, Y., Lai, C. H., Kovacs, J. J., Higashimoto, Y., Appella, E., and Yao, T. P. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J., 21: 6236-6245, 2002.
41. Li, M., Luo, J., Brooks, C. L., and Gu, W. Acetylation of p53 Inhibits Its Ubiquitination by Mdm2. J. Biol. Chem., 277: 50607-50611, 2002.
42. Nakamura, S., Roth, J. A., and Mukhopadhyay, T. Multiple lysine mutations in the C-terminal domain of p53 interfere with MDM2-dependent protein degradation and ubiquitination. Mol. Cell Biol., 20: 9391-9398, 2000.
43. Pearson, M., Carbone, R., Sebastiani, C., Cioce, M., Fagloli, M., Saito, S., Higashimoto, Y., Appella, E., Minucci, S., Pandolfi, P. P., and Pelicci, P. G. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature (Lond.), 406: 207-210, 2000.